close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Helus Pharma Inc. - Common Stock (NQ:HELP)

11.60 -0.10 (-0.85%)
Delayed Quote Updated: 12:32 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Helus Pharma Inc. - Common Stock

< Previous 1 2 3 Next >
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Changes Legal Name from Cybin Inc.
Via Investor Brand Network
News headline image
Helus Pharma Announces Completion of Legal Name Change
From Helus Pharma
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Annual and Special Meeting Results, Legal Name Change Effective Oct. 1
Via Investor Brand Network
News headline image
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
From Helus Pharma
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma (TM) (NASDAQ: HELP) (Cboe CA: HELP) Advances HLP003 Phase 3 Program, Targets Q4 2026 Topline Data
Via Investor Brand Network
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in TD Cowen Neuropsychiatry Summit
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT 
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Presents HLP003 Data From MDD Program at Psych Congress 2026
Via Investor Brand Network
News headline image
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Morgan Stanley Global Healthcare Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT. 
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT 
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Cantor Global Healthcare Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. 
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Regina Donohue Chief People Officer and Suresh Durgam to Scientific Advisory Board
Via Investor Brand Network
News headline image
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
From Helus Pharma
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Canaccord Genuity Growth Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
CEO Michael Halstead to participate in a fireside chat on Wednesday, August 12 at 12:00 p.m. EDT 
From Helus Pharma
Via GlobeNewswire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Issued on behalf of Helus Pharma (Nasdaq: HELP) 
From USA News Group
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Halstead as CEO
Via Investor Brand Network
News headline image
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Completes Enrollment in Phase 3 Depression Study
Via Investor Brand Network
Topics Intellectual Property
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data... 
Via FinancialNewsMedia
News headline image
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
From Helus Pharma
Via GlobeNewswire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
From MarketNewsUpdates.com
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.